Significant therapeutic advancements have been made over the last decade for treatment of inflammatory bowel disease (IBD), a chronic condition that includes Crohn’s disease (CD) and ulcerative colitis (UC). The inflammatory cytokine interleukin (IL)-23 has been established as an active …
To improve the quality of care for patients with Alzheimer’s disease (AD), health care professionals (HCPs) are positioned to assess brain health and provide the crucial early diagnosis, especially in diverse, underserved patient populations. HCPs must implement emerging care strategies, …
Early detection and treatment of human immunodeficiency virus (HIV) and hepatitis B and C (HBV, HCV) are paramount to mitigating the damage associated with these diseases, thus allowing patients to live longer, healthier lives; but many patients do not receive …
More than 32 million adults in the United States currently have diabetes, 90% of whom have type 2 diabetes (T2D) which can lead to both microvascular and macrovascular complications, and greatly compromise health-related quality of life (HRQoL) and confer significant …
Early detection and treatment of human immunodeficiency virus (HIV) and hepatitis B and C (HBV, HCV) are paramount to mitigating the damage associated with these diseases, thus allowing patients to live longer, healthier lives; but many patients do not receive …
Recent advances in the treatment of gynecologic cancers are promising, and education is needed to ensure that both oncology and primary care clinicians, including OB/GYNs, have a thorough knowledge of the latest clinical trial data and its translation to real-world …
Treatment for primary biliary cholangitis (PBC), a “common rare” chronic autoimmune disease of the intrahepatic bile ducts, is frequently hampered by missed or delayed diagnosis, as symptoms of PBC are often attributed to other conditions. This suboptimal recognition enables unchecked …
Treatment for primary biliary cholangitis (PBC), a “common rare” chronic autoimmune disease of the intrahepatic bile ducts, is frequently hampered by missed or delayed diagnosis, as symptoms of PBC are often attributed to other conditions. This suboptimal recognition enables unchecked …
The therapeutic armamentarium for inflammatory bowel disease (IBD) is expanding with the advent of anti–IL-23 therapies. The unique clinical profiles of new and emerging agents make it necessary that treatment decisions are guided by evolving knowledge of the science surrounding …